Dulaglutide
Also referenced as: Trulicity
A GLP-1 analogue linked to an Fc carrier, used in type 2 diabetes.
- Evidence grade
- AStrong Clinical Evidence
Strong Clinical Evidence
- Regulatory status
- FDA Approved for Specific Indication
Trulicity is FDA-approved for glycemic control in type 2 diabetes from age 10, and cardiovascular-event risk reduction in specified adults with type 2 diabetes. It is not approved for obesity.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A GLP-1 analogue linked to an Fc carrier, used in type 2 diabetes.
Trulicity is FDA-approved for glycemic control in type 2 diabetes from age 10, and cardiovascular-event risk reduction in specified adults with type 2 diabetes. It is not approved for obesity.
A diabetes or cardiovascular indication does not establish approval for obesity or healthy-person metabolic enhancement.
Why It's Being Studied
- Type 2 diabetes
- Cardiovascular risk reduction
Mechanism of Action
GLP-1 receptor activation increases glucose-dependent insulin secretion and affects glucagon, gastric emptying and appetite.
GLP-1 receptor activation increases glucose-dependent insulin secretion and affects glucagon, gastric emptying and appetite. A diabetes or cardiovascular indication does not establish approval for obesity or healthy-person metabolic enhancement.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Type 2 diabetes
- Cardiovascular risk reduction
- Subcutaneous approved medicine
Evidence Summary
Randomized diabetes and cardiovascular-outcome trials support the labeled glycemic and cardiovascular uses.
Higher tiers carry more weight. Filled tiers have evidence for Dulaglutide; tap to read it.
- Randomized diabetes and cardiovascular-outcome trials support the labeled glycemic and cardiovascular uses.
1 cited sources.
- Prescribing label1
Human clinical evidence
- Randomized diabetes and cardiovascular-outcome trials support the labeled glycemic and cardiovascular uses.
Reported Adverse Events in Research
- Gastrointestinal effects, pancreatitis, gallbladder disease and the thyroid C-cell tumor boxed warning matter.
Limitations of Current Evidence
- A diabetes or cardiovascular indication does not establish approval for obesity or healthy-person metabolic enhancement.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Dulaglutide | Trofinetide | |
|---|---|---|
| Evidence grade | A — Strong Clinical Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Subcutaneous approved medicine | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Dulaglutide — prescribing label